F-star Therapeutics, Inc. (FSTX)
| Market Cap | 159.19M |
| Revenue (ttm) | 14.17M |
| Net Income (ttm) | -36.42M |
| Shares Out | 17.02M |
| EPS (ttm) | -1.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 200,655 |
| Open | 8.09 |
| Previous Close | 7.57 |
| Day's Range | 7.61 - 8.24 |
| 52-Week Range | 1.15 - 15.50 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 31.17 (+278.3%) |
| Est. Earnings Date | Nov 3, 2021 |
About FSTX
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118, is currently being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company was incorporated in 2002 and is headquartered in C...
Financial Performance
In 2020, FSTX's revenue was $11.26 million, a decrease of -60.26% compared to the previous year's $28.32 million. Losses were -$25.62 million, 11.3% more than in 2019.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for FSTX stock is "Strong Buy" and the 12-month stock price forecast is 31.17.
News
F-star Therapeutics to Present FS120 Phase 1 Trial-in-Progress Update at ESMO 2021
Preclinical Data Indicates a Broad Therapeutic Window for F-star's First-in-Class Tetravalent Dual T cell Agonist Preclinical Data Indicates a Broad Therapeutic Window for F-star's First-in-Class Tetrav...
F-star Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next gener...
F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients
F-star Therapeutics Inc (NASDAQ: FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients. The new study will start in 2H of 2021 and include biomarker en...
F-star Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Company to Host Conference Call Today at 9 a.m. EDT Company to Host Conference Call Today at 9 a.m. EDT
Why F-star Therapeutics (FSTX) Might Surprise This Earnings Season
F-star Therapeutics (FSTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
5 Drug/Biotech Stocks Set to Outpace Q2 Earnings Estimates
Let us take a look at some drug/biotech stocks - FSTX, HALO, KNTE, RUBY and SPRB - that are poised to beat on second-quarter earnings.
F-star Therapeutics Announces Collaboration with MSD to Evaluate FS120 in Combination with KEYTRUDA
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next genera...
F-star Therapeutics to Announce Second Quarter Results and Host Conference Call on August 12, 2021
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next genera...
F-star Therapeutics Provides Interim Update on SB 11285 First-In-Human Dose-Escalation Study in Patients with Advance...
Study is Evaluating Intravenously Administered Novel STING Agonist Alone and In Combination with Atezolizumab Study is Evaluating Intravenously Administered Novel STING Agonist Alone and In Combination ...
F-star Therapeutics to Present at Upcoming Investor Conferences
Company Leadership will Speak at Ladenburg Thalmann 2021 Healthcare Conference and the William Blair 2021 Biotech Focus Conference Company Leadership will Speak at Ladenburg Thalmann 2021 Healthcare Con...
IONTAS Collaboration With F-star Enters Oncology Phase 1 Clinical Trial
CAMBRIDGE, England--(BUSINESS WIRE)--IONTAS Limited (IONTAS), a leader in the discovery and optimization of fully human antibodies, today announces that F-star Therapeutics, Inc. (NASDAQ: FSTX), has dos...
F-star Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
Company to Host Conference Call Today at 9 a.m. EDT Company to Host Conference Call Today at 9 a.m. EDT
F-star Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (Nasdaq: FSTX) (the “Company” or “F-star”), a clinical-stage biopharmaceutical company dedicate...
Study Published in Nature Shows F-Star's STING Agonist SB 11285 Enhances Preclinical Efficacy of Radiation Therapy
SB 11285 in Combination with Radiation is More Effective than Either as Monotherapy in a Murine Tumor Model
F-star Therapeutics Shows Differentiation of FS222 in 2021 AACR Poster
Study Confirms F-star's Bispecific Antibody Tetravalency is the Most Efficient Way to Induce Receptor Clustering and Activation Study Confirms F-star's Bispecific Antibody Tetravalency is the Most Effic...
F-star Therapeutics Announces Third Option Exercised by Merck KGaA, Darmstadt, Germany in Immuno-Oncology Collaboration
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 01, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next gener...
F-star Therapeutics Reports Full-Year 2020 Financial Results and Provides Corporate Update
Company to Host Conference Call Today at 9 a.m. EDT Company to Host Conference Call Today at 9 a.m. EDT
Why Cellect, Immutep, F-star, ProQR and Evofem Are Moving Thursday
Cellect Biotechnology Ltd. (NASDAQ: APOP), Immutep Limited (NASDAQ: IMMP), F-star Therapeutics, Inc. (NASDAQ: FSTX), ProQR Therapeutics N.V.
F-star Therapeutics: New Biologics Platform For Immunotherapy
F-star's antibody engineering platform is seemingly undervalued with comparable companies worth billions of dollars in equity value.
F-star Granted Composition of Matter Patent for FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1
Patent protects Company's lead clinical asset FS118 throughout Europe Patent protects Company's lead clinical asset FS118 throughout Europe
F-star Therapeutics Announces First Patient Dosed in FS222 Phase 1 Clinical Trial
FS222 is a potentially best-in-class bispecific antibody targeting CD137 (4-1BB) and PD-L1, and is the Company's third bispecific to enter clinical trials
F-star Therapeutics Completes Combination with Spring Bank Pharmaceuticals
CAMBRIDGE, England and CAMBRIDGE, Mass., Nov. 20, 2020 /PRNewswire/ -- F-star Therapeutics, Inc., (Nasdaq: FSTX, as of November 23, 2020) a clinical-stage immuno-oncology company determined to transform...
CORRECTING and REPLACING Spring Bank Pharmaceuticals Stockholders Approve Combination with F-star Therapeutics
HOPKINTON, Mass., Nov. 20, 2020 /PRNewswire/ -- Please replace the release dated November 19, 2020 with the following corrected version due to revisions to the headline. The corrected release reads: HOP...
Spring Bank Pharmaceuticals Stockholders Approve Combination with F-star Therapeutics
1-for-4 Reverse Stock Split to be Effective November 20, 2020 1-for-4 Reverse Stock Split to be Effective November 20, 2020
Spring Bank Pharmaceuticals Announces Special Dividend of Contingent Value Rights
HOPKINTON, Mass., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncolog...